Literature DB >> 15533590

Prognostic significance and different properties of survivin splicing variants in gastric cancer.

Hua Meng1, Caide Lu, Hideaki Mabuchi, Nobuhiko Tanigawa.   

Abstract

Survivin, a novel antiapoptosis gene, was identified as a member of the inhibitor of apoptosis protein (IAP) family. Unique among IAP, survivin has been found to be abundantly expressed in a wide variety of human malignancies, whereas it is undetectable in normal adult tissues. Recently, three splicing variants of survivin have been further characterized with different subcellular localization, but their different functions in carcinogenesis are largely unknown. We used real time quantitative RT-PCR to analyse survivin variants' mRNA expression levels in 77 gastric carcinoma cases whose frozen samples were available. All the cases and seven cell lines tested expressed wild-type survivin mRNA, which was not only the dominant transcript, but also was a poor prognostic biomarker (P = 0.003). Non-antiapoptosis survivin-2B mRNA was negatively correlated with tumor stage (P = 0.001) histological type (P = 0.007) and depth of tumor invasion (P = 0.031) while survivin-DeltaEx3 mRNA showed a significant reverse association with apoptosis ( P = 0.019). These data demonstrated that survivin mRNA expression levels are of important prognostic value, suggesting the significant participation of survivin-2B and survivin-DeltaEx3 in gastric cancer development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15533590     DOI: 10.1016/j.canlet.2003.12.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells.

Authors:  Irena Crnković-Mertens; Julia Semzow; Felix Hoppe-Seyler; Karin Butz
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

2.  Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis.

Authors:  Andreas Krieg; Billur Baseras; Monika Tomczak; Pablo Emilio Verde; Nikolas Hendrik Stoecklein; Wolfram Trudo Knoefel
Journal:  Mol Biol Rep       Date:  2013-08-15       Impact factor: 2.316

Review 3.  Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Authors:  Rosalia de Necochea-Campion; Chien-Shing Chen; Saied Mirshahidi; Frank D Howard; Nathan R Wall
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

4.  Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR.

Authors:  Anastasia Pavlidou; Maria Dalamaga; Christos Kroupis; George Konstantoudakis; Maria Belimezi; George Athanasas; Kleanthi Dimas
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

5.  Experimental study on Qizhu formula for modulating survivin, an inhibitor of apoptosis, in MGC-803 gastric cancer cells.

Authors:  Hao Wen; Xiaohua Wang; Zhaowei Shan
Journal:  Mol Clin Oncol       Date:  2014-03-13

6.  Expression of survivin and its splice variants in gastric cancer.

Authors:  Zhengjiang Cheng; Lihua Hu; Wenrong Fu; Qin Zhang; Xiaofeng Liao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

7.  The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population.

Authors:  Li Yang; Huaijun Zhu; Bo Zhou; Haijuan Gu; Hongli Yan; Naping Tang; Hanzhang Dong; Qingmin Sun; Rihong Cong; Guoyu Chen; Bin Wang
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

8.  Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas.

Authors:  Levent Dizdar; Monika Tomczak; Thomas A Werner; Sami A Safi; Jasmin C Riemer; Pablo E Verde; Nikolas H Stoecklein; Wolfram T Knoefel; Andreas Krieg
Journal:  Oncol Lett       Date:  2017-09-19       Impact factor: 2.967

9.  Change in Expression of Survivin Caused by Using Oxaliplatin in HCT116 Colon Cancer Cells.

Authors:  Won Jun Sohn; Jung Won Lee; Dong-Guk Park
Journal:  J Korean Soc Coloproctol       Date:  2010-08-31

10.  hnRNPA2B1 regulates the alternative splicing of BIRC5 to promote gastric cancer progression.

Authors:  Wei-Zhao Peng; Jin Zhao; Xin Liu; Chao-Feng Li; Shuang Si; Ren Ma
Journal:  Cancer Cell Int       Date:  2021-05-27       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.